Bosentan Therapy for Pulmonary Arterial Hypertension

20022,713 citationsJournal Articlebronze Open Access

Authors

Lewis J. Rubin · University of California, San Diego

David B. Badesch · University of Colorado Health

Robyn J. Barst · NewYork–Presbyterian Hospital

Nazzareno Galiè · University of Bologna

Carol M. Black · The Royal Free Hospital

Anne Keogh · St Vincent's Hospital Sydney

Tomás Pulido

Abstract

The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.

Topics & Keywords

Pulmonary Hypertension Research and Treatments Cardiovascular Issues in Pregnancy Vascular Anomalies and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 346, Issue 12, pp. 896-903

DOI: 10.1056/nejmoa012212

Field-Weighted Citation Impact: 125.75